TBRG4 Antibody
- Known as:
- TBRG4 Antibody
- Catalog number:
- 32060
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Signalway
- Gene target:
- TBRG4 Antibody
Related genes to: TBRG4 Antibody
- Gene:
- TBRG4 NIH gene
- Name:
- transforming growth factor beta regulator 4
- Previous symbol:
- -
- Synonyms:
- Cpr2, KIAA0948, H_TD2522F11.8, FASTKD4
- Chromosome:
- 7p13
- Locus Type:
- gene with protein product
- Date approved:
- 2004-02-23
- Date modifiied:
- 2014-11-19
Related products to: TBRG4 Antibody
Related articles to: TBRG4 Antibody
- Cancer is a term that evokes global concern which extends beyond a single disease entity claiming 9.7 million lives with incidence of 20 million per year. Transforming Growth Factor-β Regulator 4 (TBRG4), a mitochondrial regulatory protein, has recently emerged as a molecule of interest in several malignancies. Growing evidence also highlights its involvement in carcinomas such as hepatocellular carcinoma (HCC), lung cancer, breast cancer, and oral squamous cell carcinoma (OSCC), where altered expression of TBRG4 has been associated with cancer progression. Therefore, the current study aimed to systematically review the role of TBRG4 in cancer progression. PROSPERO registration preceded the strategic searching of electronic databases MEDLINE via PubMed, Cochrane Central, Embase, and Google Scholar. Upon comprehensive full-text assessment, ten articles meeting inclusion criteria were incorporated. ROBINS-E and QUIPS tools were used for quality assessment. In majority of the studies, TBRG4 expression-at both mRNA and protein levels was elevated in tumour tissues relative to adjacent normal tissues across multiple cancer types. Statistically significant correlations were, observed between TBRG4 expression and advanced clinical stages (III and IV) of OSCC, as well as with high histological grade (IV) and advanced tumour stages (T3 and T4) of HCC. This systematic review demonstrates that TBRG4 is closely associated with tumour progression, poor differentiation, therapeutic resistance, and diminished survival outcomes across various malignancies. These insights suggest the potential role of TBRG4 serving not only as a diagnostic adjunct (early lesion stratification in oral premalignant lesion such as leukoplakia), but also as a prognostic indicator (in OSCC and HCC), a predictive biomarker (for pharmacological response in Colorectal Cancer), and possibly as a therapeutic target. - Source: PubMed
Publication date: 2026/07/08
Khan MehwishDekate KamleshDhorajiwala ShakeebSawant ManaliWarrier Anupama - Head and neck squamous cell carcinoma (HNSC) is one of the most prevalent malignancies worldwide. PRKAR1B, a regulatory component of protein kinase A (PKA), has been widely investigated for its potential involvement in tumorigenesis across different diseases. However, its specific role in HNSC remains elusive. In this study, significant differences in PRKAR1B expression were observed across various cancer types. PRKAR1B was highly expressed in HNSC and was strongly associated with poor prognosis in HNSC patients. Moreover, it was identified as an independent prognostic factor significantly associated with clinical parameters. Correlation analysis revealed that PRKAR1B expression was associated with genes such as C7orf50, EIF3B, TBRG4, DDX56, and BRAT1. Additionally, it was associated with TMB and was correlated with the infiltration of immune cells such as M1 macrophages, activated mast cells, and eosinophils. Notably, PRKAR1B was identified as a predictive marker for the efficacy of CTLA-4 inhibitors, with high PRKAR1B expression potentially conferring superior therapeutic responses. Drug sensitivity analysis further suggested that Lapatinib and Erlotinib may be beneficial in HNSC patients with high PRKAR1B expression. Meanwhile, experiments showed that PRKAR1B knockdown inhibited HNSC cell proliferation and migration. Lastly, PRKAR1B protein expression was upregulated in clinical HNSC samples. Overall, this study thoroughly examined PRKAR1B expression and its prognostic significance in HNSC, investigated related molecular pathways and immune cell interactions, and validated its role via experiments. - Source: PubMed
Publication date: 2026/02/20
Zhao PengLi KangXiu WuFengLiu ZhaokunHuang YanxiaoJiang YoufangZhang PengPeng Lixiang - E2F transcription factors are crucial in various biological processes, including cell proliferation, differentiation, and apoptosis. However, the exact role of E2F target genes in breast cancer (BC), as well as their influence on survival and immune response, remains poorly understood. - Source: PubMed
Publication date: 2025/06/06
Nikonezhad BehnooshLotfian MaryamManavi NadiaZamani AtefehMahdevar Mohammad - IDD is commonly observed in symptomatic spinal disorders and is associated with mitochondrial dysfunction and NPC apoptosis. Current therapeutic targets remain theoretical, highlighting the need to explore alternative molecular targets. - Source: PubMed
Publication date: 2025/05/14
Cui XilongZhang FengCui DiZhang WeiWu HaoChen XiYu Haiyang - Transforming growth factor β regulator 4 (TBRG4) is upregulated in lung cancer, but its biological role and underlying mechanisms remain poorly understood. In this study, we analyzed pancancer gene expression profiles and clinical data from University of California, Santa Cruz Xena (UCSC Xena) to evaluate the prognostic significance of TBRG4 using univariate and multivariate Cox regression analyses. Genes with a Pearson correlation coefficient above 0.4 with TBRG4 in lung cancer were identified via UALCAN, followed by pathway enrichment analyses to explore their functional associations. To investigate TBRG4's role in lung cancer progression, we assessed cell proliferation, colony formation, and cell cycle alterations in lung cancer cells following TBRG4 knockdown. Western blot analysis was performed to examine the effects of TBRG4 depletion on key cell cycle regulators and epithelial-mesenchymal transition (EMT) markers. Additionally, the biological significance of TBRG4 was evaluated in vivo using a mouse xenograft model. TBRG4 knockdown significantly inhibited cell proliferation and colony formation while inducing cell cycle arrest and apoptosis in lung cancer cells. Analysis of co-expressed genes in the The Cancer Genome Atlas - Lung Adenocarcinoma (TCGA-LUAD) cohort revealed enrichment in cell cycle-related pathways, aligning with our experimental findings. Furthermore, TBRG4 depletion reduced EMT marker expression and suppressed tumor growth in vivo. Collectively, these findings suggest that TBRG4 may serve as a promising prognostic biomarker and therapeutic target in lung cancer. - Source: PubMed
Publication date: 2025/07/31
Wang AnshengGe QiaoFan ZhenkaiXia BingJin ZhaoLiu HaitaoSang HaiweiLi QicaiZhang CongliZhu Haonan